By combining anatomical fidelity with reproducibility, NRSS offers a novel way to train surgeons, validate clinical trials, and expand access to advanced techniques worldwide.
David Almeida, MD, MBA, PhD
Advertisement
Articles by David Almeida, MD, MBA, PhD
At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
3
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
4
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
5